Sanara MedTech tops revenue estimates, forecasts 2026 growth
Wound care specialist delivers 19% revenue growth in 2025, sees 13-17% increase this year driven by surgical solutions
Sanara MedTech reported preliminary fourth-quarter revenue of $27.2 million to $27.7 million, beating analyst estimates of $26.6 million, as the wound care specialist delivered strong organic growth despite headwinds from hurricane-impacted sales a year earlier.
The Fort Worth, Texas-based company, which specializes in advanced skin and wound care solutions for hospitals and healthcare facilities, said organic revenue growth reached 11% to 13% year-over-year when excluding approximately $1.8 million in BIASURGE sales from the prior year period. The preliminary results cap a fiscal year 2025 in which revenue reached approximately $103 million, up 19% from $86.7 million in 2024.
Looking ahead, Sanara forecast 2026 net revenue of $116 million to $121 million, representing growth of 13% to 17% compared to the midpoint of its 2025 outlook. The guidance assumes continued momentum in soft tissue product sales and positions the company as "a pure-play surgical business for treating surgical wounds," according to chief executive Seth Yon.
A significant development bolstering the 2026 outlook came earlier this month when Sanara announced that its BIASURGE Advanced Surgical Solution product received an Innovative Technology contract from Vizient Inc, the nation's largest provider-driven healthcare performance improvement company. The agreement, which took effect January 1, grants Vizient's extensive network of healthcare facility customers access to BIASURGE at contracted pricing and pre-negotiated terms. The contract was awarded based on recommendations from hospital experts within Vizient's client-led councils.
"We are positioning Sanara for sustainable, long-term growth and profitability in the surgical solutions market," Yon said in a statement, highlighting the Vizient contract as a key operational milestone achieved during the fourth quarter.
The company strengthened its balance sheet, ending the year with $16.6 million in cash, up from $15.9 million at the end of 2024. However, Sanara increased its long-term debt to $46 million from $30.7 million a year earlier, reflecting strategic investments to support growth initiatives. The company also noted progress on expanding its product portfolio through initiatives with Biomimetic Innovations Ltd related to OsStic.
Despite the earnings beat, Sanara's stock performance has been volatile. Shares traded around $22.25 on Friday morning, down approximately 33% over the past year and far below the 52-week high of $38.25. The stock has faced pressure despite recent analyst optimism—the average price target stands at $41.00, suggesting potential upside of roughly 80% from current levels. Both analysts covering the stock maintain buy ratings.
The company's market capitalization stands at approximately $204 million, with revenue per share of $11.86 based on trailing twelve-month results. Sanara reported a price-to-sales ratio of 2.0 times and an enterprise value-to-revenue multiple of 2.3 times, metrics that will be scrutinized as investors assess whether the 2026 growth trajectory justifies current valuations.
The upcoming official earnings report, expected March 24, will provide investors with audited financial results and additional color on the implementation of the Vizient contract. Management's commentary on market penetration of BIASURGE and the surgical solutions business will be particularly closely watched, as analysts have steadily raised estimates for Sanara MedTech in recent months.